On forums, they are presented as the perfect duo: Semax for focus, Selank for calm, two sprays up your nose and an “optimized” brain. The human evidence that might justify this stack amounts to a handful of small Russian studies in patients.
Semax and Selank are not two versions of the same nootropic. Semax is presented as more stimulating or neurotrophic, Selank as anxiolytic. But this comparison comes mainly from animal mechanisms, small Russian studies and testimonials.
In healthy adults, neither has demonstrated a robust improvement in concentration, memory or performance anxiety. In France, no medicine under these names is authorized as of August 12, 2026. So the right verdict is not “which should you choose?” but “does the level of evidence justify exposure to an unauthorized product of uncertain quality?”
Semax and Selank: what are we talking about?
The peptide Semax is a synthetic heptapeptide derived from a fragment of adrenocorticotropic hormone, modified with a Pro-Gly-Pro sequence. It has been studied in Russia in neurological settings, particularly after stroke.
The peptide Selank is a synthetic heptapeptide related to tuftsin, an immune-related peptide. It has been studied in anxiety disorders and in models involving GABAergic neurotransmission.
The basic comparison is as follows:
| Criterion | Semax | Selank |
|---|---|---|
| Molecular origin | Analogue of an ACTH fragment | Peptide analogue related to tuftsin |
| Marketing promise | Focus, memory, BDNF, neuroprotection | Calm, anxiety relief, sociability |
| Human data | Small imaging and neurological studies | Small Russian studies on anxiety |
| Frequently cited mechanisms | BDNF and neurotrophins, mainly in rats | GABAergic modulation, mainly in rats |
| Evidence in healthy adults | Insufficient | Insufficient |
| Authorization in France | None found under this name | None found under this name |
Different mechanisms do not automatically create two complementary indications.
What the Semax studies actually show
A small MRI study, not a performance trial
A study published in 2018 divided 24 volunteers between intranasal Semax and placebo. Resting-state functional MRI was performed before administration, then five and twenty minutes afterward. The researchers observed a difference in the volume of a rostral subcomponent of the default mode network.
This experiment has several limitations:
- only 14 people received Semax and 10 received placebo
- the result was an imaging signal
- no clinical improvement in concentration or memory was demonstrated
- the measurement was acute
- the study did not establish safety with repeated use
Changing a network on MRI does not mean working better for eight hours.
Neurological studies with limited applicability
A 2018 Russian publication studied 110 patients undergoing rehabilitation after ischemic stroke. It reported associations between Semax, plasma BDNF and functional recovery.
The abstract does not clearly describe double-blind randomization with placebo. The participants had experienced a stroke and were receiving rehabilitation. Even a positive result in this setting would not prove a nootropic effect in a healthy adult.
Claims of a large increase in BDNF come largely from rats. BDNF is not a universal neuroplasticity gauge, and a peripheral change does not guarantee cognitive improvement.
What the Selank studies actually show
A 2008 study compared Selank with medazepam in 62 people with generalized anxiety disorder or neurasthenia. Another publication compared Selank with phenazepam in 60 patients with various anxiety or somatoform disorders.
These studies suggested an anxiolytic effect, but they are insufficient for several reasons:
- small sample sizes
- incomplete methodological details in the available abstracts
- older comparators or ones rarely used in France
- no independent multicenter replication
- clinical populations that differ from occasional performance anxiety
- limited data on rare adverse effects and long-term outcomes
The GABA research cited in marketing consists mainly of experiments in rats or on cell membranes. It provides a pharmacological hypothesis, not proof that Selank reproduces the benefits of an established anxiety treatment without its risks.
Legal and regulatory status in France
A search conducted on August 12, 2026, found neither Semax nor Selank in the French public medicines database. No medicine bearing these names appeared in the European Medicines Agency’s medicines search either.
The regulatory conclusion must remain precise:
- they are not authorized as medicines under these names in France
- they do not become food supplements because a seller labels them “research only”
- a private certificate of analysis does not replace authorization, inspection or pharmacovigilance
- import, seizure and liability rules may depend on how the product is presented and its supply channel
The ANSM notes that only nonprescription medicines may be sold online by authorized pharmacies in France. It strongly advises against buying from websites outside the legal supply chain because of the risk of falsified medicines.
The term “gray area” is misleading if it suggests that an unauthorized spray is implicitly tolerated for self-experimentation.
The main risk: you do not always know what is in the bottle
Even if the theoretical molecule had a good profile, the actual product may differ.
Uncertainties exist at several levels:
- peptide identity
- purity and degradation products
- actual concentration per spray
- microbiological sterility
- endotoxins
- stability during transport
- preservatives and excipients
- manufacturing conditions
An HPLC chromatogram may verify the chemical purity of the tested sample. It does not prove that your bottle comes from the same batch, is sterile or delivers a consistent dose.
The guide peptides online: contamination, sterility and risks · FR explains these checks in detail.
The nasal route is not a guaranteed shortcut to the brain
Marketing often claims that a nasal spray directly bypasses the blood-brain barrier via the olfactory nerve. Nose-to-brain delivery is a field of research, but its effectiveness depends on the molecule, formulation, mucosa and device.
A spray may also be swallowed, degraded, absorbed into the blood or removed by mucociliary clearance. Without reliable human pharmacokinetic data, claiming an effect within fifteen minutes or a precise brain dose is speculation.
Possible risks include:
- nasal irritation, bleeding or congestion
- infection if the product is contaminated
- headaches, agitation or fatigue
- uncharacterized cardiovascular or neuropsychiatric effects
- interactions with psychotropic medications and stimulants
- unpredictable exposure if the mucosa is damaged
If you are pregnant, breastfeeding, under 18, have a neurological disease or psychiatric disorder, take psychotropic medication or compete in sports, do not experiment on your own. Seek medical advice.
Semax vs Selank for performance anxiety
Performance anxiety is not a single indication. It may involve occasional stage fright, social anxiety, panic disorder, caffeine overload or a sleep problem.
First, choose the intervention based on the observable mechanism:
| Main problem | First option to assess |
|---|---|
| Too much caffeine and palpitations | Reduce the dose and take it earlier |
| Recurring fear of judgment | CBT or supervised exposure therapy |
| Lack of preparation | Rehearsal under real-world conditions |
| Rumination before a presentation | Script, slow breathing and an action plan |
| Chronic inattention across multiple settings | Assessment for ADHD and differential diagnoses |
| Disabling anxiety or panic attacks | Medical or psychological consultation |
The guide to natural nootropics ranks options according to human data. It does not replace care for an anxiety disorder.
Why the Semax + Selank stack is not defensible
The marketing argument sounds elegant: Semax hits the accelerator, Selank puts the brakes on anxiety. But no robust trial has compared the combination with each peptide alone and placebo in healthy adults.
Without a factorial trial, we do not know:
- whether the effects complement or cancel each other out
- whether an interaction alters exposure
- whether adverse effects add up
- whether the feeling of flow comes from the context or expectations
- whether tolerance develops with repeated use
The absence of a published withdrawal syndrome is not proof of an absence of dependence or habituation. The data are simply insufficient.
The Verdict
Semax has some human neurological data and a small imaging study. Selank has small Russian studies on anxiety. Neither has the evidence needed to recommend nootropic use in healthy adults.
In France, the lack of authorization, uncertainty about online products and shortage of safety data outweigh the appealing mechanisms. The most rational choice is not to select a peptide, but to address the measurable cause of inattention or anxiety.
